Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JNJ 63682918 (Primary) ; JNJ 63682931 (Primary) ; JNJ 65195208 (Primary)
Indications Human papillomavirus infections
Focus Adverse reactions; First in man
Sponsors Janssen Vaccines and Prevention B.V

14 Dec 2020 Status changed from active, no longer recruiting to discontinued, due to low enrolment and increasing COVID restrictions, following an earlier enrolment pause in Aprilmade it clear that completion of the study would not be feasible
21 Sep 2020 Planned primary completion date changed from 9 Aug 2020 to 15 Oct 2020.
21 Sep 2020 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com